Pharmaceutical Benefits Under State Medical Assistance Programs, 1986
This report, part of the Pharmaceutical Benefits Under State Medical Assistance Programs series, is a compilation of data under state medical assistance programs (Title XIX) or state public medical assistance programs (prior Titles of the Social Security Act). It presents a general overview of the characteristics of state programs together with more detailed information on the pharmaceutical benefits provided.
This compilation provides the following information for each state:
- Recipient groups eligible for benefits
- Amount expended for drugs per recipient category
- Characteristics of the State Drug program
- Restrictions or limitations on drugs
- Medicaid or public health officials
- Pharmacy and medical consultants to the state program
- Pharmacy and medical advisory committees
- State medical and pharmaceutical association executives
The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...US v. Caronia: Related Resources
The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the...US v. Caronia and CER Communications
A landmark appeals court ruling could open the door for the pharmaceutical industry to discuss information about comparative effectiveness research (...
Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals
WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...NPC Conference to Address Questions on Ability to Share Health Research Findings Health
(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the...National Pharmaceutical Council Selects Five Research Projects for Funding
Washington, DC (January 30, 2012) – The National Pharmaceutical Council (NPC) today announced that it has selected five projects related to...
Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...High Stakes for Setting Research Standards
What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...CER Done Right: Why It Matters
The health care reform law is aimed at reshaping the health care landscape through the creation of many new regulations and regulatory...
PCORI Outlines Efforts to Engage Patients
Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...AEI's Gottlieb on Ability to Communicate CER Findings
American Enterprise Institute's Dr. Scott Gottlieb discusses legal and regulatory challenges facing various health care stakeholders in their...UPenn's Dr. Caplan on Communicating CER to Patients
Univ. of Pennsylvania Director of the Center for Bioethics Dr. Art Caplan outlines an ethical framework for communicating comparative effectiveness...Prioritizing CER: Assessing Public Health & Being Open With the Public
NPC Chief Science Officer Dr. Robert Dubois discusses an optimal decision-making process that could be utilized by research organizations in setting...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...US v. Caronia: Related Resources
The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the...US v. Caronia and CER Communications
A landmark appeals court ruling could open the door for the pharmaceutical industry to discuss information about comparative effectiveness research (...Research
Pharmaceutical Benefits Under State Medical Assistance Programs, 2007
This report provides a compilation of data under state medical or state public medical assistance...
Pharmaceutical Benefits Under State Medical Assistance Programs, 2005
This report, part of the Pharmaceutical Benefits Und
Pharmaceutical Benefits Under State Medical Assistance Programs, 2004
This report, part of the Pharmaceutical Benefits Und
- 1 of 40
- >
Commentary & Testimony
Living Up to Its Name? The Role of Patient-Centered Research
High Stakes for Setting Research Standards
Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
CER Done Right: Why It Matters
Medicare Part D, Adherence, and the Value of Pharmaceuticals